Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVISE: Dose-ranging study of bilateral intravitreal GS010 (Lumevoq) in ND4 Leber Hereditary Optic Neuropathy
2025-523339-20-00Phase 2Authorised
- Sponsor
- GenSight Biologics
- Start
- Dec 2025
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lenadogene nolparvovec in Leber hereditary optic neuropathy (LHON) (2 arms), sponsored by GenSight Biologics. Primary endpoint: BCVA change in study eyes at 1.5 years. Planned start Dec 2025; status: authorised.
02
Drugs
lenadogene nolparvovec
03
Conditions
Leber hereditary optic neuropathy (LHON)
Beyond the preview
Go deeper on 2025-523339-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523339-20-00.